Cellular Therapy and Transplantation | |
Combined adoptive immunotherapy with Blinatumomab and donor lymphocyte infusions in children with relapsed/refractory B-ALL after allogeneic stem cells transplantation | |
article | |
Liubov A. Tsvetkova1  Olesya V. Paina1  Polina V. Kozhokar’1  Аnastasia S. Frolova1  Zhemal Z. Rakhmanova1  Elena V. Babenko1  Elena V. Semenova1  Alexander D. Kulagin1  Ludmila S. Zubarovskaya1  | |
[1] RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantology, Pavlov University | |
关键词: B-cell acute leukemia; children; relapse; allo-HSCT; blinatumomab; donor lymphocyte infusions.; | |
DOI : 10.18620/ctt-1866-8836-2022-11-2-31-38 | |
学科分类:肿瘤学 | |
来源: Universitaetsklinikum Hamburg - Eppendorf / University Medical Center Hamburg - Eppendorf | |
【 摘 要 】
Allo-HSCT is potential curative option for high-risk pediatric B-cell acute leukemia (B-ALL), nevertheless about 30-70% of patients relapsed after allo-HSCT. Patients with relapsed/refractory (r/r) B-ALL have a dismal prognosis with 3-year probability overall survival (OS) about 20%. In this study we firstly appreciated efficacy and safety of combined adoptive immunotherapy with bispecific T-cell engager Blinatumomab and donor lymphocyte infusions (DLI) for 17 children underwent allo-HSCT and having relapse or minimal residual disease (MRD) after that. Fifteen (88%) of patients achieved a complete remission within the first 2 cycles of treatment with blinatumomab and DLI. The median relapse-free survival was 9.1 months (95% CI, 3.0 to 37.2 months) in patients who achieved CR, with the median duration follow up 13,3 months (95% CI, 10.0 to 30.3 months). The median overall survival for all patients was not reached at a median follow-up of 13.3 months (95% CI, 8.8 to 27.4 months). The Kaplan-Meier estimate overall survival was 76.5% (95% CI, 44%-92%) at a median follow-up time 13,3 months. Three children (18%) experienced drug-related adverse events grade 3 and two children (12%) had clinically significant induced "graft- versus-host disease" (GVHD). There were no fatal cases due to the therapy. Further immunotherapy options for r/r pediatric ALL may include repeated courses of combined adoptive immunotherapy, monotherapy of escalated DLI, chimeric antigen receptor T-cell therapies, checkpoint inhibitors or undergo second allo-HSCT.
【 授权许可】
CC BY
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202307080001307ZK.pdf | 229KB | download |